GMP certification for Sinovac facility

Sinovac Biotech, a leading provider of vaccines in China, has received  the Good Manufacturing Practice certification for its recently-opened  filling and packaging production facility. The certificate of compliance  has a five-year term and was issued by China's State Food and Drug  Administration following a site inspection.

The GMP certification provides for an overall annual manufacturing  capacity of 20 million doses, with the capability to produce up to 40  million doses through reasonable scheduling of activities. This  production milestone ensures that Sinovac can fully meet increasing  market demand and potential production increases for currently  commercialized products, namely Healive, Bilive and Anflu vaccines. The  plant also has the capabilities to fill and package Panflu, the  company's pandemic influenza vaccine, in order to support China's  prevention and control strategy against a potential outbreak of pandemic  influenza.